Brief: Biocytogen Have Reached Agreement With Xencor, Inc., For Licensing Of Co's Fully Human Antibody Renmab/Renlite
07/12/2020 20:01
Dec 7 (Reuters) - BIOCYTOGEN:
* BIOCYTOGEN - HAVE REACHED AGREEMENT WITH XENCOR, INC., FOR
LICENSING OF CO'S FULLY HUMAN ANTIBODY RENMAB/RENLITE
Source text for Eikon: ID:nPrerqGfZa
Further company coverage: XNCR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Xencor
See all newsXencor, Inc. reports results for the quarter ended June 30 - Earnings Summary
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments
Brief: Xencor Q2 EPS USD -0.29
Brief: Xencor To Receive $105 Million From Alexion To Resolve Ultomiris® U.S. Royalty Matter
Xencor Q1 revenue falls sharply and misses estimates